J. Ferlay, E. Steliarova-foucher, and J. Lortet-tieulent, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, vol.49, pp.1374-1403, 2013.

L. Watson, P. Wyld, and D. Catovsky, Disease burden of chronic lymphocytic leukaemia within the European Union, Eur J Haematol, vol.81, pp.253-258, 2008.

S. H. Swerdlow, E. Campo, and S. A. Pileri, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-2390, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

P. Sujobert, Y. L. Bris, and L. Leval, Definition of a minimal genes set for mature lymphoid blood diseases, Hématologie, vol.1, issue.2, pp.27-59, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01870189

R. Rosenquist, A. Rosenwald, and M. Du, Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-theart and beyond, Haematologica, vol.101, pp.1002-1009, 2016.

M. Gerlinger, A. J. Rowan, and S. Horswell, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, vol.366, pp.883-892, 2012.

S. Araf, J. Wang, and K. Korfi, Genomic profiling reveals spatial intratumor heterogeneity in follicular lymphoma, Leukemia, vol.32, pp.1258-1263, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01815695

D. A. Landau, S. L. Carter, and P. Stojanov, Evolution and impact of subclonal mutations in chronic lymphocytic leukemia, Cell, vol.152, pp.714-726, 2013.

D. M. Kurtz, F. Scherer, and M. C. Jin, Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma, J Clin Oncol, vol.36, pp.2845-2853, 2018.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011.

S. C. Mack, H. Witt, and R. M. Piro, Epigenomic alterations define lethal CIMP-positive ependymomas of infancy, Nature, vol.506, pp.445-450, 2014.

D. M. Hyman, I. Puzanov, and V. Subbiah, Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations, N Engl J Med, vol.373, pp.726-736, 2015.

L. Tourneau, C. Delord, J. Gonçalves, and A. , Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proofof-concept, randomised, controlled phase 2 trial, Lancet Oncol, vol.16, pp.1324-1334, 2015.

A. Guyard, A. Boyez, and A. Pujals, DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks, Virchows Arch Int J Pathol, vol.471, pp.491-500, 2017.

C. Williams, F. Pontén, and C. Moberg, A high frequency of sequence alterations is due to formalin fixation of archival specimens, Am J Pathol, vol.155, pp.1467-1471, 1999.

M. M. Li, M. Datto, and E. J. Duncavage, Standards and guidelines for the interpretation and reporting of sequence variants in cancer, J Mol Diagn, vol.19, pp.4-23, 2017.

V. Jurinovic, R. Kridel, and A. M. Staiger, Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy, Blood, vol.128, pp.1112-1120, 2016.

A. Pastore, V. Jurinovic, and R. Kridel, Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, Lancet Oncol, vol.16, pp.1111-1122, 2015.

C. S. Zent and W. R. Burack, Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53, Hematol Am Soc Hematol Educ Program, pp.119-124, 2014.

A. Reddy, J. Zhang, and N. S. Davis, Genetic and functional drivers of diffuse large B cell lymphoma, Cell, vol.171, pp.481-494, 2017.

R. Schmitz, G. W. Wright, and D. W. Huang, Genetics and pathogenesis of diffuse large B-cell lymphoma, N Engl J Med, vol.378, pp.1396-1407, 2018.

B. Chapuy, C. Stewart, and A. J. Dunford, Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes, Nat Med, vol.24, pp.679-690, 2018.

F. Morschhauser, G. Salles, and P. Mckay, Interim report from a phase 2 multicenter study of tazeùetostat, an EZH2 inhibitor, in patients with relapsed or refractory B-cell non Hodgkin lymphomas, Hematol Oncol, vol.35, pp.24-25, 2017.

S. P. Treon, C. K. Tripsas, and K. Meid, Ibrutinib in previously treated Waldenström's macroglobulinemia, N Engl J Med, vol.372, pp.1430-1440, 2015.

R. Rahal, M. Frick, and R. Romero, Pharmacological and genomic profiling identifies NF-kB-targeted treatment strategies for mantle cell lymphoma, Nat Med, vol.20, pp.87-92, 2014.

J. A. Woyach, R. R. Furman, and T. Liu, Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib, N Engl J Med, vol.370, pp.2286-2294, 2014.

F. Lemonnier, J. Dupuis, and P. Sujobert, Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic Tcell lymphoma, Blood, vol.132, pp.2305-2309, 2018.

Y. Guillermin, J. Lopez, and K. Chabane, What does this mutation mean? The tools and pitfalls of variant interpretation in lymphoid malignancies, Int J Mol Sci, vol.19, p.1251, 2018.